Inflammation

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.

In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.

Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.

Dupilumab treatment delivered at a specialized tertiary care center has great potential to improve patient clinical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP).

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.

Health status and health-related quality of life (QOL) outcomes were compared between patients with severe cases of chronic rhinosinusitis with nasal polyps (CRSwNP) and a general patient population.

Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.

A research letter highlighted recent findings that iREACH educational intervention training may be helpful in preventing peanut allergies.

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.

Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.

The Skin Pain Numeric Rating Scale, Worst-Itch Numeric Rating Scale, and Dermatology Life Quality Index were evaluated for their content validity, fit-for-purpose, and psychometric and measurement properties among patients with the chronic skin disease being treated with dupilumab.

Using a clustering algorithm, researchers were able to identify inflammatory and noninflammatory subsets of the disease, which may account for varying responses to certain treatments.

The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).

This review and meta-analysis included 34 studies covering 1762 patients, and investigated the efficacy of 4 varieties of dietary treatment for eosinophilic esophagitis (EoE).

Such cases of eosinophilic esophagitis (EoE) are rare, but they can be treated with the typical therapies for EoE.

Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.

Outcomes were investigated among 541 patients who had chronic rhinosinusitis; they accounted for 435 primary surgeries and 106 revisionist surgeries.

Although it is well studied in adult patients, there is a lack of research on eosinophilic gastrointestinal disorders (EGIDs) among pediatric patients; a recent study aimed to add to the clinical knowledge of EGIDs in younger patients.

The utility of and adherence to follow-up exams for potential recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) was investigated among 60 patients who had undergone functional endoscopic sinus surgery.

Disease outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) that related to inflammation and endotype specification were goals in this new study that evaluated the biomarker potential of S100A4.

Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.